USD 10.26 Billion
Antibody Drug Conjugates (ADC) Market Size, Share, Growth Analysis, By Product (Kadcyla, Enhertu), By Linker Type (Cleavable Linkers, Non-Cleavable Linkers), By Target Type (HER2, CD22), By Payload Type (Monomethyl Auristatin E, Calicheamicin), By Disease Type, By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2342 |
Region:
Global |
Published Date: November, 2024
Pages:
208
|Tables:
126
|Figures:
67
Antibody Drug Conjugates (ADC) Market Insights
Global Antibody Drug Conjugates (ADC) Market size was valued at USD 8.41 billion in 2022 and is poised to grow from USD 9.70 billion in 2023 to USD 30.09 billion by 2031, growing at a CAGR of 15.2% in the forecast period (2024-2031).
The surging cases of cancer around the world and rising demand for novel drugs and pharmaceuticals are projected to drive sales of antibody drug conjugates over the coming years. Rising investments in biopharmaceutical research and advancements in antibody drug conjugate development technologies are also expected to drive antibody drug conjugates market growth in the future. Moreover, the rising availability of expedited approval pathways for antibody drug conjugates to reduce their time-to-market is also anticipated to bolster the sales of antibody drug conjugates across the study period and beyond. Increasing popularity of personalized medicine and growing adoption of the same will also act in favor of antibody drug conjugates market development going forward. On the contrary, high costs of development, safety concerns regarding toxicity, and competition from biosimilars are key restraints that trouble antibody drug conjugates companies around the world.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Adcetris
Fastest Growth
Trodelvy
Growth Rate
9.2% CAGR
Antibody Drug Conjugates (ADC) Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Antibody Drug Conjugates (ADC) Market Segmental Analysis
Global Antibody Drug Conjugates (ADC) Market is segmented on the product, linker type, target type, payload type, disease type, and region. By product, market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Other Products. By linker type, market is segmented into Cleavable Linkers and Non-Cleavable Linkers. By target type, market is segmented into HER2, CD22, CD30, and Other Target Types. By payload type, market is segmented into Monomethyl Auristatin E (MMAE), Calicheamicin, Maytansinoids, and Other Payload Types. By disease type, market is segmented into Breast Cancer, Blood Cancer, and Other Disease Types. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Application
Breast cancer is projected to spearhead the demand for antibody drug conjugates across the study period. Surging incidence of breast cancer and rising awareness regarding the same around the world are contributing to the dominance of this segment. Growing availability of promising antibody drug conjugates for the treatment of breast cancer and rising use of Kadcyla for the same are also expected to contribute to the high market share of this segment.
On the other hand, the demand for antibody drug conjugates for blood cancer applications is projected to surge at an impressive pace in the future. Increasing cases of lymphoma and leukemia around the world are projected to bolster antibody drug conjugates sales in this segment. Rising approval of new antibody drug conjugates for the treatment and management of blood cancer indications will also bolster market growth in the long run.
Analysis by Technology
Cleavable linker technology is projected to bring in major revenue for antibody drug conjugates companies across the forecast period. This technology is preferred as it allows antibody drug conjugates to stay in the bloodstream longer and release cytotoxins to provide effective patient outcomes. The technology also takes advantage of differences in normal and tumor cells to effectively identify its target and improve the scope of treatment. All these benefits allow this segment to hold a high market share.
Meanwhile, the demand for non-cleavable linker technology is expected to increase at a notable pace across the study period. Growing adoption of Kadcyla is estimated to be a key factor promoting market growth via this segment. Preference for this technology can be linked to its overall reduced cytotoxicity that does not cause harm to the surrounding healthy cells. However, low number of antibody drug conjugates with this technology could limit the market share of this segment in the future.
Antibody Drug Conjugates (ADC) Market By Linker Type
To get detailed analysis on other segments, Request For Free Sample Report
Antibody Drug Conjugates (ADC) Market Regional Insights
North America is projected to account for a dominant share of the global antibody drug conjugates market. Presence of a strong medical research infrastructure, supportive government funding for research, and rapid adoption of advanced healthcare technologies and products are key factors allowing North America to lead global antibody drug conjugates demand outlook. The United States is forecasted to account for a major chunk of the revenue in this region for antibody drug conjugates companies. Surging prevalence of cancer and growing geriatric population will also boost antibody drug conjugates demand going forward.
The surging prevalence of cancer in the Asia Pacific region makes it the fastest-growing market for antibody drug conjugates companies in the world. Growing investments in healthcare infrastructure development, rising oncology research activity, and increasing acceptance of novel cancer treatments are expected to create new opportunities for antibody drug conjugates providers going forward. The presence of multiple contract research organizations in this region will also bolster antibody drug conjugates market growth in this region. India, China, and Japan are slated to be the most opportune markets for antibody drug conjugates companies in this region.
Antibody Drug Conjugates (ADC) Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Antibody Drug Conjugates (ADC) Market Dynamics
Drivers
Surging Prevalence of Cancer
- Cancer has become a worldwide public health issue as the cases of cancer keep on rising. This surge in prevalence has led to increased oncology research and high demand for drugs and treatments, which in turn is projected to boost sales of antibody drug conjugates as well.
Favorable Regulatory Approval Process
- The proven efficacy of antibody drug conjugates in managing and treating different types of cancer has pushed regulatory authorities to create expedited pathways for antibody drug conjugates to reduce their time-to-market. This favorable regulatory scenario is also expected to bolster antibody drug conjugates market growth in the future.
Restraints
High Costs of Manufacturing
- Manufacturing antibody drug conjugates requires specialized equipment, facilities, and a skilled workforce. All of these require substantial investments and therefore drive up the costs of manufacturing and result in an expensive product which ultimately slows down market development.
Safety Concerns
- Antibody drug conjugates are also faced with some severe safety concerns owing to their toxic effects on non-targeted tissues and cells. This off-target toxicity can cause complications in a patient’s health, and this is why these safety concerns impede antibody drug conjugates demand outlook.
Request Free Customization of this report to help us to meet your business objectives.
Antibody Drug Conjugates (ADC) Market Competitive Landscape
Investing in the development of antibody drug conjugates for different cancer indications should remain the prime focus of all companies. Market players should also focus on developing antibody drug conjugates for other chronic diseases to expand their business scope. Targeting developing countries could offer good returns on investment in the long run. Collaborations and partnerships could help antibody drug conjugates companies fast-track their R&D process and improve scope of commercialization as well.
Top Player’s Company Profiles
- Roche Holding AG (Switzerland)
- Daiichi Sankyo Company, Limited (Japan)
- Gilead Sciences, Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Pfizer Inc. (US)
- Astellas Pharma Inc. (Japan)
- AstraZeneca (UK)
- ADC Therapeutics SA (Switzerland)
- ImmunoGen, Inc. (US)
- Zydus Group (India)
- AbbVie Inc. (US)
- Ambrx (US)
- LegoChem Biosciences, Inc. (South Korea)
- Byondis (Netherlands)
- ProfoundBio (US)
- RemeGen (China)
- Sutro Biopharma, Inc. (US)
- Lepu Biopharma Co., Ltd. (China)
- Zymeworks Inc. (Canada)
- Mersana Therapeutics (US)
- Duality Biologics (China)
- Lanova Medicines (China)
- Exelixis, Inc. (US)
- BioNeCure Therapeutics Inc. (US)
- Tripartite Therapeutics, Inc. (US)
Antibody Drug Conjugates (ADC) Key Market Trends
- Development of Antibody Drug Conjugates for Other Chronic Indications: Currently, most antibody drug conjugates are targeted towards cancer indications, but antibody drug conjugates companies can explore application in other indications to maximize their business scope going forward. Increasing investments in development of antibody drug conjugates for the treatment of a wide range of chronic diseases will offer multiple rewarding opportunities in the future.
- Use of Antibody drug conjugates in Combination Therapies: The demand and popularity of combination therapies for the treatment of multiple chronic diseases is increasing rapidly around the world and antibody drug conjugates companies can explore the use of their offerings in these therapies. This could help improve patient outcomes and further boost sales of antibody drug conjugates in the long run,
Antibody Drug Conjugates (ADC) Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing prevalence of chronic diseases and rising demand for personalized medicine are projected to bolster the demand for antibody drug conjugates over the coming years. However, high costs of manufacturing and safety concerns are estimated to impede antibody drug conjugates market growth potential in the future. North America is projected to lead the demand for antibody drug conjugates owing to high prevalence of cancer and presence of key biopharmaceutical companies. Use in combination therapies and development of antibody drug conjugates for other diseases will offer new opportunities for market players in the long run.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 8.41 billion |
| Market size value in 2031 | USD 30.09 billion |
| Growth Rate | 15.2% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Antibody Drug Conjugates (ADC) Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Antibody Drug Conjugates (ADC) Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Antibody Drug Conjugates (ADC) Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Antibody Drug Conjugates (ADC) Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Antibody Drug Conjugates (ADC) Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Antibody Drug Conjugates (ADC) Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
